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Background: The pleiotropic effects of 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which
are independent from their cholesterol-lowering action, have been widely recognized in various biological systems.
Statins can affect endothelial homeostasis, which is partly modulated by the production of nitric oxide (NO).
However, it is unclear how statin/NO-mediated posttranslational S-nitrosylation of endothelial proteins and
changes in translational profiles may benefit endothelial integrity. Therefore, it is important to understand the
statin/NO-mediated S-nitrosylation in endothelial cells.
Results: Rosuvastatin treatment of human umbilical vein endothelial cells (ECs) enhanced the enzymatic activity of
endothelial nitric oxide synthase (eNOS) and the expression of 78 S-nitrosoproteins. Among these S-nitrosoproteins,
we identified 17 proteins, including protein disulfide bond isomerase, phospholipase C, transaldolase and heat
shock proteins. Furthermore, a hydrophobic Cys66 was determined as the S-nitrosylation site of the mitochondrial
HSP70. In addition to the statin-modulated posttranslational S-nitrosylation, changes in the NO-mediated
translational proteome were also observed. Seventeen major proteins were significantly upregulated after
rosuvastatin treatment. However, 12 of these proteins were downregulated after pretreating ECs with an eNOS
inhibitor (L-NAME), which indicated that their expression was modulated by NO.
Conclusions: ECs treated with rosuvastatin increase eNOS activation. The increased NO production is involved in
modulating S-nitrosylation and translation of proteins. We provide further evidence of the pleiotropic effect of
rosuvastatin on endothelial physiology.
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The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, commonly referred to as sta-
tins, are prescribed to patients to improve serum lipid
profiles. The cholesterol-independent pleiotropic effects
of statins include improvement of endothelial function,
reduction of oxidative stress, prevention of platelet ag-
gregation and stabilization of atherosclerotic plaques [1].
Statins exert a protective effect against plaque inflamma-
tion and rupture by the reduction of cyclooxygenase-2
and matrix metallopeptidase-9 expression [2]. Statins* Correspondence: lingwang@ibms.sinica.edu.tw
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reproduction in any medium, provided the oralso increase the expression of heme oxygenase-1, which
is involved in the stress response [3]. Increasing evidence
suggests that nitric oxide (NO) plays a role in these
statin-mediated pleiotropic effects. Statin treatment
increases endothelial nitric oxide synthase (eNOS) ex-
pression by enhancing eNOS mRNA stability [4]. Statins
promote eNOS activity through the AMP-activated pro-
tein kinase (AMPK) and PI3K/Akt pathways [5,6]. This
statin-mediated eNOS activation exerts antioxidant
effects that decrease reactive oxygen species production
[7]. Upregulation of eNOS by statins protects against
stroke [8]. Statins induce eNOS activation during
hypoxia-induced pulmonary hypertension [9]. Krueppel-
like factor-2, a transcription factor responsible for eNOS
expression, is upregulated after statin treatment [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between NO and a reactive cysteine thiol to form S-
nitrosothiol. This cGMP-independent posttranslational
modification contributes to various stimuli-mediated cel-
lular signaling [11]. S-nitrosylation can influence protein
structure/conformation and enzyme activity. Studies
have suggested that S-nitrosylation prevents thiols from
irreversible oxidative modification [5,12]. S-nitrosylation
has emerged as a fundamental protein modification that
is essential for normal cardiovascular function. It is con-
ceivable that NO-mediated S-nitrosylation and protein
expression contribute to statin-induced pleiotropic
effects.
Rosuvastatin is hydrophilic and possesses the lowest
inhibition coefficient (IC50 =5.4 nM) compared with the
other statins [13]. Rosuvastatin protects the vasculature
by attenuating the release of inflammatory mediators
and by suppressing monocyte adhesion. In addition, the
activation of c-Jun N-terminal kinases and nuclear factor
kappa-light-chain-enhancer of activated B cells is inhib-
ited after rosuvastatin treatment [14]. Mice pretreated
with rosuvastatin show increased endothelial NO pro-
duction and attenuated myocardial necrosis after ische-
mia/reperfusion [15]. In the clinical setting, patients that
switch to rosuvastatin from other statins have signifi-
cantly lower low-density lipoprotein levels [16].
Considering the rapid progress in proteomics research,
it would be interesting to determine the role of NO on
rosuvastatin-exerted pleiotropic effects. In the current
study, we found that human endothelial cells (ECs) trea-
ted with rosuvastatin stimulated eNOS activity with a
subsequent increase in S-nitrosylation of endothelial
proteins. By using a modified biotin switch approach, we
identified the S-nitrosoproteome regulated by rosuvasta-
tin. Moreover, endothelial protein expression was
increased after rosuvastatin treatment, but it was sup-
pressed by pretreating ECs with an eNOS inhibitor, indi-
cating that NO modulates rosuvastatin-mediated
proteins expression. Our results provide an opportunity
to further elucidate the detailed mechanisms by which
statin-regulated NO production contributes to lipid-
lowering-independent pleiotropic effects.
Results
Rosuvastatin activates eNOS and increases protein
S-nitrosylation
In this study, ECs treated with increasing concentrations
(0.1, 1 and 10 μM) of rosuvastatin for 24 hours showed an
enhanced eNOS expression and a greater phosphorylation
of eNOS at ser1177 residue (peNOSS1177) compared with
controls (Figure 1A). Consistently, rosuvastatin (10 μM)
treatment for various time intervals (0.5, 6 and 24 h) also
resulted in increased eNOS expression and peNOSS1177
compared with controls (Figure 1B). There was a greaterthan 3-fold increase of eNOS activation after rosuvastatin
treatment. By using the modified biotin switch method
coupled with western blot-based DTT-free 2-DE, rosuvas-
tatin treatment resulted in a time-dependent increase in
S-nitrosylation of protein that occurred at the same time
as rosuvastatin-elevated eNOS activation (Figure 1C). The
increased amount of S-nitrosoproteins were detected
(24 ± 9, 38± 11, 59± 16 and 78± 22) from control and
rosuvastatin treatments (0.5, 6 and 24 h).
Rosuvastatin increases S-nitrosylation in a
posttranslational manner
To determine if rosuvastatin-induced S-nitrosylation is a
posttranslational event, western blotting and LC-MS/MS
were applied (Figure 2a). Briefly, VisPRO staining
showed total protein levels and western blotting showed
protein modification status. Upon image analysis of
western blots, 17 proteins (ES1-ES17) from rosuvastatin-
treated ECs showed a significant increase in S-
nitrosylation compared with that in control ECs (relative
fold ≥1.5, Figure 3A). VisPRO staining showed that the
expression of the proteins mentioned above was not
affected by rosuvastatin treatment (relative fold between
0.8–1.3), except for proteins at spots ES3 and ES14
(Figure 3B). Our results suggest that increased S-
nitrosylation is mainly a posttranslational event.
Verification of S-nitrosylation of protein and the
nitrosylated site
As shown in Figure 2B, the biotinylated lysate was sepa-
rated by a 2-DE gel and analyzed by mass spectrometry.
Rosuvastatin-induced S-nitrosoproteins were identified
that included protein disulfide isomerase-related protein
(PDIRP), PDI A3 precursor (PDIA3), HSP60, HSP70,
mitochondrial heat shock protein 70 (mt-HSP70) and
phospholipase C (Table 1). Further analysis using the
MASCOT in-house algorithm against the NCBInr data-
base identified Cys66 as the biotinylated (i.e., S-nitrosy-
lated) site of mt-HSP70 (Figure 4A), and it was located
in a hydrophobic region of this protein (Figure 4B). To
further verify the S-nitrosoproteins detected by mass
spectrometry, the biotinylated lysate was subjected to
pull-down assay as described in Figure 2C. Lysates be-
fore and after neutravidin pull-down (PD) were analyzed
by western blotting using antibodies against tropomyosin
(TPM) and vimentin (VIM) (Figure 5). TPM and VIM
exhibited a 5.6- and 4.2-fold increase in S-nitrosylation
compared with controls.
Nitric oxide is involved in rosuvastatin-modulated protein
expression
The translational proteome in ECs after 24 h of rosuvasta-
tin (10 μM) treatment was analyzed by 2-DE (Figure 6A).
Seventeen major proteins were upregulated (U1-U17) with
Figure 1 Rosuvastatin increases eNOS activation and subsequent protein S-nitrosylation in ECs. (A) Protein lysates (40 μg) extracted from
ECs treated with rosuvastatin (0.1 μM, 1 μM and 10 μM) for 24 h, or (B) rosuvastatin (10 μM) for 0.5, 6, and 24 h were separated by SDS-PAGE and
western blotting with antibodies against eNOS (1:3000), phospho-eNOSS1177 (peNOSS1177, 1:3000) and β-actin (1:5000). The relative fold eNOS and
peNOSS1177 are shown by mean± S.E. compared with control treatment. #p< 0.05, *p< 0.01 from three separate experiments by using Fisher’s
LSD. (C) One milligram of biotin-switch-derived biotinylated lysate collected from ECs with rosuvastatin (10 μM) treatment for various intervals
(0.5, 6 and 24 h) was analyzed by western blot-based 2-DE (streptavidin-HRP, 1:3000). The spot numbers detected on the 2-DE x-ray films are
shown as mean± S.E. from three independent experiments.
Huang et al. Proteome Science 2012, 10:43 Page 3 of 11
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trometric analysis, these proteins were functionally cate-
gorized as being involved in lipid metabolism (TIP47),
energy regulation (glucose-3-phosphate dehydrogenase,
lactate dehydrogenase, transaldolase, cytochrome c oxi-
dase, mt-ATP synthase beta subunit, and F0 complex),
angiogenesis (glia maturation factor and galectin-1) and
antioxidant-related proteins (glutaredoxin and ubiquinol-
cytochrome c reductase) (Table 2). Interestingly, 12 of
those 17 statin-upregulated proteins were suppressed
when ECs were co-treated with the eNOS inhibitor NG-
nitro-L-arginine methyl ester (L-NAME, Figure 6B), indi-
cating that NO is involved in rosuvastatin-modulated
protein expression in ECs.
Discussion
Statins have been widely used as lipid-lowering drugs
prescribed to patients with cardiovascular diseases ormetabolic disorders. Of particular interest, statins have
been shown to increase bioavailability of NO and to pro-
tect against vascular inflammation and cardiac cell death
[1,3]. Among NO-mediated effects, NO-induced S-nitro-
sylation of proteins has been recognized as a fundamen-
tal posttranslational modification of proteins [5]. This
S-nitrosylation of proteins may exert statin-mediated
pleiotropic effects in vascular ECs. In the current study,
rosuvastatin increased eNOS and activation in a sus-
tained manner (Figure 1), which is consistent with a pre-
vious study [15]. The increased S-nitrosylation of
proteins was analyzed by a modified biotin switch
method as previously described [17]. This approach has
an advantage over other reported methodologies [18-20].
Further MS/MS analysis and use of a software algorithm
identified the S-nitrosylated site of mt-HSP70 (Cys66)
with a protein mass shift of 428.2 Da. To confirm the ac-
curacy of the MS/MS data, the S-nitrosylation of two
Figure 2 Biotin switch method to detect protein S-nitrosylation. As shown in the flowchart, the biotin switch was performed by a three-step
reaction. (A) The biotinylated lysates were subjected to DTT-free (non-reduced) 2-DE that was stained by VisPRO dye to determine translational
levels (total protein). Western blotting was subsequently performed by hybridization with streptavidin-HRP to determine posttranslational
S-nitrosylation levels. (B) Another separated 2-DE gel was prepared for the pecking of the S-nitrosoproteins and then it was analyzed by mass
spectrometry. (C) The biotinylated lysates were also applied to a pull-down assay by neutravidin agarose to assure that the identified proteins
were biotinylated (i.e. S-nitrosylated).
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ive antibodies (Figure 5). These S-nitrosylated proteins
are heterogeneous in function and may play protective
roles for the pleiotropic effects induced by this lipid-
lowering drug.
HSPs exert a chaperon function and are involved in
protection as well as pathogenesis of various tissues [21].
In our study, three HSPs were identified with character-
istics of enhanced S-nitrosylation. HSP60 and HSP70
are involved in the development of atherosclerosis [21].Mt-HSP70 has been identified as a HSP60 receptor on
the cell surface, and it participates in autoantibody-
induced endothelial apoptosis [22]. The protective effects
of statins on the vascular system may be partially caused
by S-nitrosylation of these HSPs due to the known bene-
fit of statins on endothelial integrity. Our previous study
demonstrated that ECs under shear flow enhance the S-
nitrosylation of HSP70 [23]. S-nitrosylation of Cys597 in
HSP90 reduces the ability to activate eNOS [24]. In
the present study, S-nitrosylation of Cys66 on the
Figure 3 Rosuvastatin-induced protein S-nitrosylation is a posttranslational event. (A) The 2-DE gels were stained by VisPRO dye to
evaluate translational levels. Western blotting was subsequently performed to determine posttranslational levels. Open triangles indicate reference
proteins in each gel and x-ray film for confirming the accurate position of each protein spot. Protein spots with increased S-nitrosylation are
indicated by arrowheads. (B) Rosuvastatin-induced changes at the translational level (column labeled “VisPRO”) and posttranslational
S-nitrosylation (column labeled “western blot”) of each S-nitrosoprotein represented as relative fold changes (black bar/gray bar). Statistical data
are shown as mean± S.E. from three separate experiments.
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http://www.proteomesci.com/content/10/1/43hydrophobic region of mt-HSP70 is consistent with the
S-nitrosylation consensus motif that is surrounded by
the hydrophobic microenvironment [25]. S-nitrosylation









ES1 HSP70 21040386 73.8/6.0
ES2 HSP70 21040386 73.8/6.0
ES3 ER-60 protease 1208427 57.2/5.9
ES4 HSP60 31542947 61.0/5.7
ES5 mt-HSP70 b) 14917005 59.2/5.9
ES6 Vimentin 340219 53.6/5.0
ES7 Vimentin 340219 53.6/5.0
ES8 Vimentin 340219 53.6/5.0
ES9 Tubulin 34740335 50.1/4.9
ES10 PDI-related protein 1710248 46.2/5.0
ES11 PDI A3 precursor 729433 56.9/6.2
ES12 Beta-actin 4501885 41.7/5.3
ES13 Beta-actin 4501885 41.7/5.3
ES14 Phospholipase C-alpha 303618 57.1/6.2
ES15 Transaldolase 5803187 37.7/6.4
ES16 Tropomyosin 3 55665775 29.1/4.8
ES17 Tropomyosin 3 55665775 29.1/4.8
a) The function of the protein was obtained via the MASCOT software (www.matrix
were set as follows: peptide mass tolerance: ± 0.4 Da; allowed missed cleavage: 1.
b) Accession number from the NCBInr database.
c) Protein molecular weight and pI annotated in the database.
d) Protein molecular weight and pI calculated from 2-DE gels.previously suggested [26]. It is unknown whether S-
nitrosylation alters HSP properties that contribute to









76.3/5.8 47 670 24
75.8/5.8 50 717 29
82.5/4.6 26 442 8
63.4/5.6 24 337 10
57.2/5.8 34 257 12
56.4/4.8 65 998 26
56.2/4.7 49 798 21
55.8/4.6 55 824 23
55.0/4.6 32 367 11
56.3/5.0 20 284 7
55.4/6.4 37 571 11
57.2/5.2 61 872 21
56.4/5.1 42 605 14
64.2/5.7 11 194 3
54.8/5.6 16 269 6
34.5/4.7 27 371 6
28.6/4.6 28 395 7
science.com) search program by querying the NCBInr database. The parameters
Figure 4 Cys66 of mitochondrial heat shock protein 70 is the S-nitrosylation site. (A) MS/MS data for peptide fragments from
mitochondrial heat shock protein 70 (mt-HSP70) were searched against the NCBInr protein database using a MASCOT in-house algorithm using
the precursor ion m/z tolerance of 6 ppm. The biotinylated eptides were identified by a mass shift of 428.2 Da. (B) The hydrophobicity of the
region containing the S-nitrosylated cysteine (Cys66) was predicted by HYDROPHOBICITY PLOT software.
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http://www.proteomesci.com/content/10/1/43Protein disulfide isomerase (PDI) catalyzes the forma-
tion and breakage of disulfide bonds within proteins. S-
nitrosylation abrogates PDI-attenuated neurotoxicity
[27]. PDI has also been identified as an “NO carrier”Figure 5 Rosuvastatin-induced S-nitrosylation of vimentin and tropom
biotin switch method were liquot and separated by SDS-PAGE following w
tropomyosin (TPM). These lysates were assigned as “before pull-down” (PD
neutravidin-agarose to PD biotinylated proteins and assigned as “after PD”.
same antibodies. The relative fold “before PD” and “after PD” changes are s
three separate experiments by using Fisher’s LSD.that facilitates the introduction of NO from outside the
cell via S-nitrosylation/de-nitrosylation [28]. Our previ-
ous studies showed that ECs exposed to shear flow or
an NO donor increase S-nitrosylation of PDI andyosin. Forty micrograms of biotinylated lysates derived from the
estern blotting with antibodies against vimentin (VIM) and
). The other biotinylated lysates (~500 μg) were incubated with 10 μl
The pulled-down lysates then underwent western blotting with the
hown by mean± S.E. compared with control treatment. *p< 0.01 from
Figure 6 Rosuvastatin regulates protein expression in a NO-dependent manner. (A) Protein lysates (1 mg) from ECs treated with
rosuvastatin (10 μM) alone or with rosuvastatin in the presence of L-NAME (1 mM) for 24 h were subjected to 2-DE. Results are shown by VisPRO
staining. Arrows indicate the proteins that were upregulated by rosuvastatin. (B) Each asterisk indicates a protein that was upregulated by
rosuvastatin but was suppressed by L-NAME co-treatment. The relative fold change in protein level is shown by spot density as mean± S.E. from
three separate experiments.
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related protein (ES10) and PDI A3 precursor (ES11)
were found to be S-nitrosylated in statin-treated ECs.
S-nitrosylation of these PDI-related proteins may bephysiologically important for maintaining endothelial
integrity.
In the current study, three cytoskeletal proteins, vimen-
tin (intermediate filaments), tubulin (microtubules) and
Table 2 Rosuvastatin-modulated proteins identified by LC-MS/MS
Spot
number












U1 Mitochondrial ATP synthase beta subunit precursor 32189394 51.8/5.0 48.6/5.0 63 1177 22
U2 ER-60 protease 1208427 57.2/5.9 56.5/5.9 54 687 28
U3 Ubiquinol-cytochrome c reductase core I protein 515634 53.2/5.9 46.7/5.7 58 507 23
U4 Cargo selection protein TIP47 3095186 47.2/5.3 45.1/5.3 41 473 15
U5 Transaldolase 5803187 37.7/6.4 36.5/6.1 44 216 16
U6 L-lactate dehydrogenase B 4557032 36.9/5.7 35.7/5.9 40 505 15
U7 Eukaryotic translation initiation factor 3, subunit
2 beta
4503513 36.9/5.4 36.6/5.6 38 273 11
U8 Glyceraldehyde-3-phosphate dehydrogenase 31645 36.2/8.26 36.2/5.5 22 297 6
U9 Annexin V, chain A 157833780 36.0/4.9 35.1/5.1 27 125 11
U10 Glia maturation factor, beta 4758442 16.7/5.2 26.5/5.4 45 208 8
U11 SH3 domain binding glutamic acid-rich protein-like 4506925 12.8/5.2 16.2/5.5 20 91 2
U12 Enhancer of rudimentary homolog 4758302 12.3/5.6 12.8/5.6 17 61 12
U13 Phosphohistidine phosphatase 1 isoform 3 24475861 13.8/5.7 14.4/5.8 26 137 5
U14 Cytochrome c oxidase subunit V precursor 190885499 16.8/6.3 14.2/5.3 22 99 4
U15 Galectin-1 4504981 14.7/5.7 14.5/5.0 38 190 5
U16 ATP synthase, H+ transporting, mitochondrial
F0 complex, subunit d, isoform a
5453559 18.5/5.2 22.6/5.4 31 127 5
U17 Rho GDP dissociation inhibitor (GDI) beta 56676393 23.0/5.1 26.7/5.2 27 140 7
a) The function of the protein was obtained via the MASCOT software (www.matrixscience.com) search program by querying the NCBInr database. The parameters
were set as follows: peptide mass tolerance: ± 0.4 Da; allowed missed cleavage: 1.
b) Accession number from the NCBInr database.
c) Protein molecular weight and pI annotated in the database.
d) Protein molecular weight and pI calculated from 2-DE gels.
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http://www.proteomesci.com/content/10/1/43actin (microfilaments) were identified with enhanced S-
nitrosylation under rosuvastatin treatment. In addition,
TPM, which regulates actin movement, was also found to
be S-nitrosylated. These proteins are involved in the regu-
lation of cell shape, cell adhesion and migration. Previous
studies have indicated that these proteins could be S-
nitrosylated under certain conditions [29,30]. It is unclear
whether S-nitrosylation of these cytoskeletal proteins
affects endothelial migration after statin treatment.
In addition to rosuvastatin-mediated posttranslational
S-nitrosylation, we also investigated translational protein
levels. Some proteins were shown to be upregulated by
rosuvastatin treatment and then suppressed by L-NAME
pretreatment, indicating that NO participates in
rosuvastatin-induced protein expression. These proteins
were functionally grouped into glucose homeostasis
(lactate dehydrogenase and glucose-3-phosphate de-
hydrogenase), energy production (cytochrome c oxidase
and mt-ATPase F0 complex), protein folding (ER-60
protease) and anti-inflammation (Rho GDP dissociation
inhibitor [GDI]). ER-60 protease (U2) is a cysteine prote-
ase that degrades misfolded proteins in the endoplasmic
reticulum [31]. Rho-family proteins act as activators of a
number of nuclear transcription factors that may reduce
NO production and promote inflammatory responses viathe Rho-Rho kinase pathway. We also identified a nega-
tive regulator of Rho proteins, Rho GDI [3]. Statins have
been found to disrupt the interaction between Rho and
Rho GDI, and therefore, negatively regulate Rho-family
function, which is consistent with the anti-inflammatory
effect of rosuvastatin [32].
Our results clearly indicated that rosuvastatin treat-
ment increased S-nitrosylation of proteins and altered
protein expression. The detailed mechanisms of the pro-
tein expression modulated by rosuvastatin-induced NO
remain unclear and need to be further investigated.
Nevertheless, these posttranslational S-nitrosoproteomes
and translational proteomes provide a basis for further
study on the pleiotropic effects of statins in the cardio-
vascular system.
Conclusions
Pleiotropic effects of statins have attracted attention from
therapeutic and clinical researchers. By using a modified
biotin switch methodology, we were able to identify 17 S-
nitrosoproteomes regulated by rosuvastatin. In addition,
L-NAME treatment confirmed that nitric oxide plays an
important role in endothelial protein expression. Our
results provide further evidence of the detailed mechan-
isms of statin/NO-mediated pleiotropic effects.
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EC culture
ECs were isolated from the human umbilical cord as
described previously [33]. The experimental procedure
conformed to the principles outlined in the 1964 Declar-
ation of Helsinki for the use of human tissue or subjects.
ECs were cultured in M199 medium supplemented with
fetal bovine serum (20%, v/v), streptomycin (100 μg/ml)
and penicillin (100 U/ml). ECs were replaced with M199
medium containing 2% (v/v) fetal bovine serum and
were incubated overnight prior to rosuvastatin (AstraZe-
neca, Taipei, Taiwan) treatment. To evaluate whether
protein expression was NO-dependent, ECs were co-
incubated with an eNOS inhibitor, (L-NAME, 1 mM;
Calbiochem) and rosuvastatin (10 μM) for 24 h.
Cell lysis and protein extraction
ECs after rosuvastatin treatment were washed with cord
buffer (0.14 M NaCl, 4 mM KCl, 11 mM glucose, and
10 mM HEPES, pH 7.4), and then lysed with 300 μl lysis
buffer (250 mM Hepes, pH 7.7, 1 mM EDTA, 0.1 mM
neocuproine and 0.4%,w/v CHAPS). After centrifugation
at 10,000 × g for 10 min at 4°C, the supernatant was col-
lected, and the protein concentration of the supernatant
was determined with the BCA assay (Thermo Fisher Sci-
entific Inc., USA).
Two-DE
For 2-DE separation, protein lysates were precipitated
with ice-cold acetone at −20°C. After centrifugation, the
protein pellets were air-dried and dissolved in sample
buffer (9 M urea, 2%, w/v CHAPS,60 mM DL-
dithiothreitol [DTT], and 2% v/v IPG solution, pH 4–7,
GE Healthcare, USA) at room temperature for 30 min.
The denatured proteins were mixed with rehydration
buffer (8 M urea, 2%w/v CHAPS, 0.5% v/v IPG solution,
pH 4–7, and 30 mM DTT) and soaked into an 18-cm
DryStrip (pH 4–7, GE Healthcare) for up to 12 h using
an Ettan IPGphor system (GE Healthcare). After isoelec-
tric focusing at an accumulated voltage of 60 kVh, the
strip gels were incubated with equilibration buffer
(2%w/v SDS, 50 mM Tris–HCl, pH 8.8, 6 M urea,
30% v/v glycerol and 60 mM DTT) for 20 min, and then
they were equilibrated with the same buffer containing
iodoacetic acid (IAA, 135 mM) for an additional 20 min.
The equilibrated isoelectric focusing strip was placed on
the top of a vertical SDS-PAGE to separate proteins.
Biotin-switch
S-nitrosylation was determined by the biotin switch
method as previously described by Jaffrey [34]. In brief,
the treated ECs were washed with cold buffer (10 mM
Hepes, pH 7.4, 0.14 M NaCl, 4 mM KCl and 11 mM
glucose). Cell lysates were obtained with lysis buffer(250 mM Hepes, pH 7.7, 1 mM EDTA, 0.1 mM neocu-
proine, and 0.4%w/v CHAPS). Free thiols in the protein
extracts (0.8 mg/ml) were methylated with blocking buf-
fer (225 mM Hepes, pH 7.7, 0.9 mM EDTA, 0.09 mM
neocuproine, 2.5%w/v SDS and 20 mM MMTS) at 50°C
for 20 min with agitation. MMTS-treated lysate was pre-
cipitated with cold acetone and the resulting pellet was
resuspended in HENS buffer (250 mM Hepes, pH 7.7,
1 mM EDTA, 0.1 mM neocuproine and 1%w/v SDS).
This was followed by addition of HENS buffer contain-
ing 4 mMN-[6-(biotinamido)hexyl]-3′-(2′-pyridyldithio)
propionamide (biotin-HPDP/DMF) mixed with 1 mM
sodium ascorbate. The protein lysate:biotin-HPDP mix-
ture was incubated at room temperature for 1 h to allow
biotinylation to occur. These mixtures were precipitated
with cold acetone to remove excess biotin-HPDP and
then stored at −20°C for subsequent studies.
Detection of biotinylated proteins with non-reduced 2-DE
In the current study, biotinylated lysates derived from
the biotin switch were dissolved in the buffers acquired
for 2-DE analysis. To prevent the dissociation of labeled
biotin molecules, DTT was excluded from those buffers
that were used for the translational proteome as
described in the above section. Two-DE gels were
stained with VisPRO (Visual Protein Biotech, Taipei, Tai-
wan) to determine protein translational levels, and then
western blotting was performed with streptavidin-HRP
(1:3000) to determine proteins that were posttranslation-
ally S-nitrosylated. Western blotted membranes were
developed with Super Signal West Femto reagent
(Thermo Fisher Scientific) and exposed to X-ray film.
The X-ray film and the VisPRO-stained gel were scanned
by a digital scanner (Microtek, International Inc., Taipei,
Taiwan). Results were analyzed by Progenesis Samespots
v2.0 software (NonLinear Dynamics, UK). The proteins
with increased S-nitrosylation were collected from a sep-
arate 2-DE gel with VisPRO staining and were subjected
to mass analysis as previously described [17].
Mass spectrometry analysis
Excised gel slices were digested with trypsin for 4 h at
37°C (In-Gel Tryptic Digestion kit, Thermo Fisher Sci-
entific). The tryptic peptides were desalted on a pro-
teomics C18 column (Mass Solution Ltd., Taiwan) and
subjected to mass analysis by CapLC/Q-TOF (Micro-
mass, UK). Mass spectrometry data were searched
against the NCBInr database using a MASCOT in-
house search program (Matrixscience, UK). Peptides
containing a biotinylated cysteine were determined
with the mass shift of 428.2 Da. Search parameters
were set as follows: mass values, monoisotopic; protein
mass, unrestricted; peptide mass tolerance, ± 0.4 Da;
fragment mass tolerance, ± 0.4 Da; and maximum
Huang et al. Proteome Science 2012, 10:43 Page 10 of 11
http://www.proteomesci.com/content/10/1/43missed cleavages, 1. The hydrophobicity of S-nitrosylated
cysteine (Cys66) was predicted by HYDROPHOBICITY
PLOT software on the website (http://www.bmm.icnet.
uk/~offman01/hydro.html).
Purification of biotinylated protein
The biotinylated proteins (i.e., the S-nitrosoproteins)
were pulled down using neutravidin-agarose beads
(15 μl/per mg of initiated protein input) in neutralization
buffer (20 mM Hepes, pH 7.7, 100 mM NaCl, 1 mM
EDTA and 0.5% v/v Triton X-100). The agarose beads
were rinsed with washing buffer (20 mM Hepes, pH 7.7,
600 mM NaCl, 1 mM EDTA and 0.5% v/v Triton X-100),
and then incubated with elution buffer (20 mM Hepes,
pH 7.7, 100 mM NaCl, 1 mM EDTA and 100 mM 2-
mercaptoethanol) for 20 min at 37°C, with gentle agita-
tion to release neutravidin-bound proteins. These eluted
biotinylated proteins were mixed with SDS-PAGE sam-
ple buffer (2%w/v SDS, 50 mM Tris–HCl, pH 6.8,
30% v/v glycerol and 100 mM 2-mercaptoethanol) to
perform SDS-PAGE and western blotting to validate S-
nitrosylation of protein detected in 2-DE.
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